Feed FBIOX
FB

Fidelity Select Biotechnology Pt FBIOX NASDAQ · Financials · United States

$29.09 +0.00% +$0.00

Summary

Fidelity Select Biotechnology Pt is a mutual fund run by Fidelity. It does not trade on an exchange: you buy it from the fund company at a price set once a day. Positions inside: 234. The ten largest make up 47% of the fund.

Positions
234
Dividend yield
5.58%
Running since
1985

What speaks for it

  • It has been running since 1985.

What to watch

  • 100% of the fund is in one sector (Healthcare).
  • 84% of the fund is in one country (United States).
  • In the last five years its price once dropped by 55% from its high.

A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.

Price

Performance

1 month
+6.6%
3 months
-1.5%
This year
+15%
1 year
+17%
3 years
+96%
5 years
+34%
10 years
+50%
Avg. market cap
$112.6B
P/E
32.9x
Forward P/E
-
P/S
10.9x
P/B
7.1x
P/FCF
29.8x
EV/EBITDA
24.5x
Dividend yield
0.53%
ROIC
-7.9%
ROE
-36.9%
Gross margin
-88.7%
Operating margin
-3,924.3%
Net margin
-3,654.3%
Payout ratio
17.4%
Net debt/EBITDA
0.7x
Beta
0.70

Weighted average of the 50 largest companies, which make up 81% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.

What is inside?

Moderately concentrated
  1. 1
    AB
    AbbVie ABBV 11%
  2. 2
    KR
    Krystal Biotech KRYS 10%
  3. 3
    AM
    Amgen AMGN 7.5%
  4. 4
    MR
    Moderna MRNA 4.5%
  5. 5
    RV
    Revolution Medicines RVMD 2.7%
  6. 6
    NT
    Natera NTRA 2.4%
  7. 7
    IN
    Insmed INSM 2.4%
  8. 8
    AR
    Argenx ARGX 2.3%
  9. 9
    PR
    Praxis Precision Medicines, Inc. PRAX 2.0%
  10. 10
    AS
    Ascendis Pharma ASND 1.8%

Positions in the fund: 234. The ten largest make up 47% of it.

Composition as of Nov 14, 2026.

Where is it spread?

One sector dominates

By sector

By country

By company size

By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.

Largest sector: Healthcare (100%). Largest country: United States (84%). Largest size group: Mid cap (38%).

What does it cost me?

We do not know the costs of this fund.

How has it done?

Growing slowly
A year on average, 10 years
+4.1%
Deepest drop
-55%
Yearly volatility
26%

Average yearly growth over the last ten years: 4.1%. Deepest drop in these years: 55% below the earlier high.

Does it pay dividends?

Yes, it pays out
Yield
5.58%
Payments a year
2
Last payment
$1.06

Over the last 12 months it paid $1.62 per share, which is 5.58% of today's price. The last payment was $1.06 on Apr 10, 2026.

How expensive are the companies inside?

Rather expensive
P/E of the companies inside
32.9
Average Bulios Score
50 out of 100

Weight by Bulios Fair Price

On average the companies inside trade for 32.9 times their yearly profit. By Fair Price, 65% of the rated weight comes out as overvalued.

Counted from its largest companies (50), which make up 81% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.

Can I buy it as an ETF?

A mutual fund is bought from the fund company. These ETFs hold much of the same and trade on an exchange, so an ordinary broker carries them.

Fund Domicile Size 1-year change Dividends
IB
IBB iShares Biotechnology ETF
United States 0.44% $11.0B +29% Pays out 44%
CU
CURE.AX Global X - S&P Biotech ETF
Australia 0.45% $27.2M +30% Reinvests 43%
XB
XBI SPDR S&P Biotech ETF
United States 0.35% $7.87B +32% Pays out 43%
2B
2B70.DE iShares Nasdaq US Biotechnology UCITS ETF
Ireland 0.35% $948.6M +36% Reinvests 43%
IB
IBBQ Invesco Nasdaq Biotechnology ETF
United States 0.19% $84.6M +30% Pays out 43%
TD
TDNA T. Rowe Price Biotech ETF
United States 0.55% $9.87M - - 43%

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy